Details of the Drug

General Information of Drug (ID: DMHIDUE)

Drug Name
Phenelzine
Synonyms
Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2], [3]
Skin imperfections EK71 Patented [4]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 136.19
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 19.8 mcg/L [5]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 43 min [5]
Elimination
The elimination of the administered dose is mainly composed of the phenelzine metabolites, phenylacetic acid and parahydroxyphenylacetic acid that constitute 79% of the dose found in the urine in the first 96 hours [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 11.6 hours [5]
Chemical Identifiers
Formula
C8H12N2
IUPAC Name
2-phenylethylhydrazine
Canonical SMILES
C1=CC=C(C=C1)CCNN
InChI
InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
InChIKey
RMUCZJUITONUFY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3675
ChEBI ID
CHEBI:8060
CAS Number
51-71-8
DrugBank ID
DB00780
TTD ID
D0P9AC
INTEDE ID
DR1272
ACDINA ID
D00524

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [4]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monoamine oxidase type B (MAO-B) DTT MAOB 2.65E-02 1.12E-02 0.07
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Phenelzine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Phenelzine and Sertraline. Depression [6A70-6A7Z] [49]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Phenelzine and Cyclobenzaprine. Depression [6A70-6A7Z] [50]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Phenelzine and Vilazodone. Depression [6A70-6A7Z] [51]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Phenelzine and Nefazodone. Depression [6A70-6A7Z] [51]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Phenelzine and Vortioxetine. Depression [6A70-6A7Z] [49]
Isocarboxazid DMAF1NB Major Additive hypertensive effects by the combination of Phenelzine and Isocarboxazid. Depression [6A70-6A7Z] [52]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Phenelzine and Milnacipran. Depression [6A70-6A7Z] [51]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Phenelzine and Desvenlafaxine. Depression [6A70-6A7Z] [51]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Phenelzine and Clomipramine. Depression [6A70-6A7Z] [50]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Phenelzine and Doxepin. Depression [6A70-6A7Z] [53]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Phenelzine and Esketamine. Depression [6A70-6A7Z] [54]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Phenelzine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Phenelzine and Methylene blue. Acquired methaemoglobinaemia [3A93] [50]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Repaglinide. Acute diabete complication [5A2Y] [55]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Glibenclamide. Acute diabete complication [5A2Y] [55]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Tolazamide. Acute diabete complication [5A2Y] [55]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Insulin-glulisine. Acute diabete complication [5A2Y] [55]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Insulin-aspart. Acute diabete complication [5A2Y] [56]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Glipizide. Acute diabete complication [5A2Y] [55]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Phenelzine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [57]
Tripelennamine DMZBU15 Moderate Additive CNS depression effects by the combination of Phenelzine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [57]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Phenelzine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [58]
Bepridil DM0RKS4 Moderate Additive hypotensive effects by the combination of Phenelzine and Bepridil. Angina pectoris [BA40] [58]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Phenelzine and Nifedipine. Angina pectoris [BA40] [58]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Phenelzine and Levalbuterol. Asthma [CA23] [59]
Pirbuterol DMI5678 Moderate Additive hypertensive effects by the combination of Phenelzine and Pirbuterol. Asthma [CA23] [60]
Ephedrine DMMV0KW Moderate Decreased metabolism of Phenelzine caused by Ephedrine mediated inhibition of non-CYP450 enzyme. Asthma [CA23] [61]
Salbutamol DMN9CWF Moderate Additive hypertensive effects by the combination of Phenelzine and Salbutamol. Asthma [CA23] [59]
Formoterol DMSOURV Moderate Additive hypertensive effects by the combination of Phenelzine and Formoterol. Asthma [CA23] [60]
Lisdexamfetamine DM6W8V5 Major Increased risk of hyperpyrexia by the combination of Phenelzine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [58]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Phenelzine and Desipramine. Attention deficit hyperactivity disorder [6A05] [50]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Phenelzine and Droxidopa. Autonomic nervous system disorder [8D87] [62]
Pseudoephedrine DMIVJ0D Major Additive hypertensive effects by the combination of Phenelzine and Pseudoephedrine. Breathing abnormality [MD11] [58]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Phenelzine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [60]
Vilanterol DMF5EK1 Moderate Additive hypertensive effects by the combination of Phenelzine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [59]
Salmeterol DMIEU69 Moderate Additive hypertensive effects by the combination of Phenelzine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [60]
Indacaterol DMQJHR7 Moderate Additive hypertensive effects by the combination of Phenelzine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [60]
Arformoterol DMYM974 Moderate Additive hypertensive effects by the combination of Phenelzine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [60]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Phenelzine and Levomilnacipran. Chronic pain [MG30] [51]
Isoproterenol DMK7MEY Moderate Additive hypertensive effects by the combination of Phenelzine and Isoproterenol. Conduction disorder [BC63] [59]
Cocaine DMSOX7I Major Increased risk of hyperpyrexia by the combination of Phenelzine and Cocaine. Corneal disease [9A76-9A78] [63]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Phenelzine and Ethanol. Cystitis [GC00] [64]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Phenelzine and Cyclandelate. Dementia [6D80-6D8Z] [58]
LEVONORDEFRIN DMWDJ0H Moderate Additive hypertensive effects by the combination of Phenelzine and LEVONORDEFRIN. Discovery agent [N.A.] [65]
Tetrabenazine DMYWQ0O Major Additive hypertensive effects by the combination of Phenelzine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [66]
Deutetrabenazine DMUPFLI Major Additive hypertensive effects by the combination of Phenelzine and Deutetrabenazine. Dystonic disorder [8A02] [66]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Phenelzine and Diphenhydramine. Episodic vestibular syndrome [AB31] [57]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Phenelzine and Ethacrynic acid. Essential hypertension [BA00] [67]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Phenelzine and Phenoxybenzamine. Essential hypertension [BA00] [58]
Guanethidine DM9NSWT Moderate Antagonize the effect of Phenelzine when combined with Guanethidine. Essential hypertension [BA00] [68]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Phenelzine and Mephentermine. Essential hypertension [BA00] [58]
Oxymetazoline DM8ZXT6 Moderate Decreased metabolism of Phenelzine caused by Oxymetazoline mediated inhibition of non-CYP450 enzyme. Eyelid inflammatory disorder [9A02] [61]
Solifenacin DMG592Q Minor Additive anticholinergic effects by the combination of Phenelzine and Solifenacin. Functional bladder disorder [GC50] [69]
Propantheline DM2EN6G Minor Additive anticholinergic effects by the combination of Phenelzine and Propantheline. Gastric ulcer [DA60] [69]
Dobutamine DMD1B8Z Moderate Additive hypertensive effects by the combination of Phenelzine and Dobutamine. Heart failure [BD10-BD1Z] [58]
Nesiritide DMFOIA8 Moderate Additive hypotensive effects by the combination of Phenelzine and Nesiritide. Heart failure [BD10-BD1Z] [58]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Phenelzine and Chlorothiazide. Heart failure [BD10-BD1Z] [58]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Phenelzine and Bumetanide. Heart failure [BD10-BD1Z] [58]
Tetrahydrozoline DMT57WC Moderate Decreased metabolism of Phenelzine caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme. Herpes simplex infection [1F00] [61]
Procarbazine DMIK367 Major Additive hypertensive effects by the combination of Phenelzine and Procarbazine. Hodgkin lymphoma [2B30] [52]
Maraviroc DMTL94F Moderate Additive hypotensive effects by the combination of Phenelzine and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [58]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Phenelzine and Isosorbide mononitrate. Hydrocephalus [8D64] [58]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Phenelzine and Eprosartan. Hypertension [BA00-BA04] [58]
Aliskiren DM1BV7W Moderate Additive hypotensive effects by the combination of Phenelzine and Aliskiren. Hypertension [BA00-BA04] [58]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Phenelzine and Captopril. Hypertension [BA00-BA04] [58]
Methyldopa DM5I621 Major Decreased metabolism of Phenelzine caused by Methyldopa mediated inhibition of non-CYP450 enzyme. Hypertension [BA00-BA04] [68]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Phenelzine and Levamlodipine. Hypertension [BA00-BA04] [58]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Phenelzine and TAK-491. Hypertension [BA00-BA04] [58]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Phenelzine and Fenoldopam. Hypertension [BA00-BA04] [58]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Phenelzine and Indapamide. Hypertension [BA00-BA04] [58]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Phenelzine and Trichlormethiazide. Hypertension [BA00-BA04] [58]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Phenelzine and Diazoxide. Hypertension [BA00-BA04] [58]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Phenelzine and Perindopril. Hypertension [BA00-BA04] [58]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Phenelzine and Felodipine. Hypertension [BA00-BA04] [58]
Deserpidine DMRH7CV Moderate Additive hypertensive effects by the combination of Phenelzine and Deserpidine. Hypertension [BA00-BA04] [70]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Phenelzine and Telmisartan. Hypertension [BA00-BA04] [58]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Phenelzine and Irbesartan. Hypertension [BA00-BA04] [58]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Phenelzine and Hydralazine. Hypertension [BA00-BA04] [58]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Phenelzine and Clevidipine butyrate. Hypertension [BA00-BA04] [58]
Belladonna DM2RBWK Minor Additive anticholinergic effects by the combination of Phenelzine and Belladonna. Infectious gastroenteritis/colitis [1A40] [69]
Dicyclomine DMZSDGX Minor Additive anticholinergic effects by the combination of Phenelzine and Dicyclomine. Irritable bowel syndrome [DD91] [69]
Naphazoline DMJFZDL Moderate Decreased metabolism of Phenelzine caused by Naphazoline mediated inhibition of non-CYP450 enzyme. Itching [1F28-1G07] [61]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Phenelzine and Almogran. Migraine [8A80] [71]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Phenelzine and Frovatriptan. Migraine [8A80] [71]
Rizatriptan DMDJMA3 Major Decreased metabolism of Phenelzine caused by Rizatriptan mediated inhibition of non-CYP450 enzyme. Migraine [8A80] [71]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Phenelzine and Naratriptan. Migraine [8A80] [71]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Phenelzine and Lasmiditan. Migraine [8A80] [51]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Phenelzine and Flibanserin. Mood disorder [6A60-6E23] [72]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Phenelzine and Thalidomide. Multiple myeloma [2A83] [73]
Ozanimod DMT6AM2 Major Decreased metabolism of Phenelzine caused by Ozanimod mediated inhibition of non-CYP450 enzyme. Multiple sclerosis [8A40] [74]
Dextroamphetamine DMMIHVP Major Increased risk of hyperpyrexia by the combination of Phenelzine and Dextroamphetamine. Narcolepsy [7A20] [58]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Phenelzine and Phenindamine. Nasopharyngitis [CA00] [57]
Dimenhydrinate DM264B3 Minor Additive anticholinergic effects by the combination of Phenelzine and Dimenhydrinate. Nausea/vomiting [MD90] [69]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Phenelzine and Promethazine. Nausea/vomiting [MD90] [58]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Phenelzine and Cyclizine. Nausea/vomiting [MD90] [57]
Metoclopramide DMFA5MY Moderate Increased risk of hyperpyrexia by the combination of Phenelzine and Metoclopramide. Nausea/vomiting [MD90] [75]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Phenelzine and Ondansetron. Nausea/vomiting [MD90] [57]
Bupropion DM5PCS7 Major Additive hypertensive effects by the combination of Phenelzine and Bupropion. Nicotine use disorder [6C4A] [70]
Phendimetrazine DM6TS1N Major Increased risk of hyperpyrexia by the combination of Phenelzine and Phendimetrazine. Obesity [5B80-5B81] [58]
Amfepramone DM9YSNQ Major Increased risk of hyperpyrexia by the combination of Phenelzine and Amfepramone. Obesity [5B80-5B81] [58]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Phenelzine and Sibutramine. Obesity [5B80-5B81] [51]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Phenelzine and Lorcaserin. Obesity [5B80-5B81] [76]
Benzphetamine DMIJATC Major Increased risk of hyperpyrexia by the combination of Phenelzine and Benzphetamine. Obesity [5B80-5B81] [58]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Phenelzine and Dexfenfluramine. Obesity [5B80-5B81] [51]
Propylhexedrine DMTBW2O Moderate Decreased metabolism of Phenelzine caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme. Obesity [5B80-5B81] [61]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Phenelzine and Polythiazide. Oedema [MG29] [58]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Phenelzine and Lofexidine. Opioid use disorder [6C43] [58]
Apraclonidine DMO4PVE Major Additive hypertensive effects by the combination of Phenelzine and Apraclonidine. Optic nerve disorder [9C40] [70]
Methamphetamine DMPM4SK Major Additive hypertensive effects by the combination of Phenelzine and Methamphetamine. Pain [MG30-MG3Z] [77]
Biperiden DME78OA Minor Additive anticholinergic effects by the combination of Phenelzine and Biperiden. Parkinsonism [8A00] [78]
Levodopa DMN3E57 Major Additive hypertensive effects by the combination of Phenelzine and Levodopa. Parkinsonism [8A00] [58]
Dopamine DMPGUCF Major Increased risk of hyperpyrexia by the combination of Phenelzine and Dopamine. Parkinsonism [8A00] [58]
Ritodrine DM4V6RL Moderate Additive hypertensive effects by the combination of Phenelzine and Ritodrine. Preterm labour/delivery [JB00] [60]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Phenelzine and Terazosin. Prostate hyperplasia [GA90] [58]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Phenelzine and Silodosin. Prostate hyperplasia [GA90] [58]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Phenelzine and Levomepromazine. Psychotic disorder [6A20-6A25] [58]
Selexipag DMAHSU0 Moderate Additive hypotensive effects by the combination of Phenelzine and Selexipag. Pulmonary hypertension [BB01] [58]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Phenelzine and Tolazoline. Pulmonary hypertension [BB01] [58]
Epoprostenol DMUTYR2 Moderate Additive hypotensive effects by the combination of Phenelzine and Epoprostenol. Pulmonary hypertension [BB01] [58]
Iloprost DMVPZBE Moderate Additive hypotensive effects by the combination of Phenelzine and Iloprost. Pulmonary hypertension [BB01] [58]
Mesoridazine DM2ZGAN Moderate Additive CNS depression effects by the combination of Phenelzine and Mesoridazine. Schizophrenia [6A20] [58]
Trifluoperazine DMKBYWI Moderate Additive CNS depression effects by the combination of Phenelzine and Trifluoperazine. Schizophrenia [6A20] [58]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Phenelzine and Avanafil. Sexual dysfunction [HA00-HA01] [58]
Tadalafil DMJZHT1 Moderate Additive hypotensive effects by the combination of Phenelzine and Tadalafil. Sexual dysfunction [HA00-HA01] [58]
Vardenafil DMTBGW8 Moderate Additive hypotensive effects by the combination of Phenelzine and Vardenafil. Sexual dysfunction [HA00-HA01] [58]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Phenelzine and Papaverine. Tonus and reflex abnormality [MB47] [58]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Tolbutamide. Type 2 diabetes mellitus [5A11] [55]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [55]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Phenelzine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [55]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Phenelzine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [57]
Methdilazine DMAUHQX Moderate Additive CNS depression effects by the combination of Phenelzine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [58]
Brompheniramine DMFOVSD Moderate Additive CNS depression effects by the combination of Phenelzine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [57]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Phenelzine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [57]
⏷ Show the Full List of 121 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Edetate disodium E00186 8759 Complexing agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Phenelzine 15 mg tablet 15 mg Oral Tablet Oral
Phenelzine Sulfate 15mg/tablet tablet 15mg/tablet Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7266).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011909.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
5 New Zealand report
6 Robinson DS, Cooper TB, Jindal SP, Corcella J, Lutz T: Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. J Clin Psychopharmacol. 1985 Dec;5(6):333-7.
7 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
8 An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
19 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
20 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
21 Drug Interactions Flockhart Table
22 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
23 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
24 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
25 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
26 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
27 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
28 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
29 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
30 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
31 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
32 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
33 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
34 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
35 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
36 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
37 Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
38 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
39 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
40 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
41 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
43 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
44 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
45 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
46 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
47 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
48 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
49 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
50 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
51 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
52 Bazire SR "Sudden death associated with switching monoamine oxidase inhibitors." Drug Intell Clin Pharm 20 (1986): 954-6. [PMID: 3816543]
53 Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30. [PMID: 942286]
54 Cerner Multum, Inc. "Australian Product Information.".
55 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
56 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
57 Canadian Pharmacists Association.
58 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
59 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
60 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
61 Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
62 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
63 Product Information. Cocaine Hydrochloride Nasal (cocaine nasal). Genus Lifesciences Inc., Allentown, PA.
64 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
65 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
66 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
67 Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
68 Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
69 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
70 De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
71 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
72 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
73 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
74 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
75 Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
76 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
77 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
78 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.